Janssen secures a ‘yes, but’ MSAC response as Gilead strengthens its lead with an important recommendation and expanded people focus.
He’s a well-known face in pharma having worked at Merck, Shire and Sanofi, and now he’s notched up an early win as a first-time GM.
Ozempic or Wegovy? Mounjaro or Zepound? With some therapies now getting two names, what do they actually mean?
Is the high proportion of recommendation walk-aways and fails just the beginning if one HTA Review savings option becomes reality?
As the LSDP expert panel prepares to meet this week, we look at what happened to the ultra-rare therapy considered at its last meeting.
Boosters may be available but it seems Australians prefer to live with the virus, with 97 per cent of adults aged 18-64 now unprotected.
Inks new deal as Biocon finds a new Aussie partner and biosimilars amass in global pipelines, ready to target three more blockbusters.
First opioids and now spinal cord stimulators. Should companies walk away from pain rather than risk more reputational damage?